Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 2CNS 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Recurrent 1Glioblastoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × TEMPOL-H × Clear all
NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04337099 2021-05-05

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Matrix Biomed, Inc.

Available
Genitourinary

Prostatic Neoplasms

NCT04874506 2021-05-05

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡